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IntroDuctIon
Epicardial adipose tissue (EAT) is the adipose tissue that lies 
immediately around the myocardium. EAT is in direct contact 
with both the myocardium itself and the coronary vessels, and 
it is surrounded by the visceral pericardium.1
Since the early 2000s, EAT has become the object of many 
studies concerning biomarkers of cardiovascular risk, as 
its volume has been shown to be correlated to the inci-
dence of pathologies such as metabolic syndrome, coro-
nary atherosclerosis, or atrial fibrillation (AF).2 In recent 
years, interest has shifted onto a precise EAT quantifi-
cation, to potentially establish it as a reliable and non- 
invasive biomarker for cardiovascular risk.3
Epicardial adipose tissue anatomy and 
physiology
EAT is non- homogeneously distributed around the heart. 
Most of it lies at the cardiac base and apex, in the cardiac 
grooves and around the coronary arteries, and it is thicker 
around the right ventricle than around the left ventricle.4 
Additional adipose tissue surrounding the heart, the so- called 
paracardial adipose tissue (PAT), can be found outside the 
parietal pericardium. The whole pericardial fat is defined 
as the sum of EAT and PAT.5 Figure 1 shows the respective 
localizations of these two fat deposits on a contrast- enhanced 
cardiac CT (CCT) scan.
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abstract
Epicardial adipose tissue (EAT) is a metabolically activated beige adipose tissue, non- homogeneously surrounding 
the myocardium. Physiologically, EAT regulates toxic fatty acids, protects the coronary arteries against mechanical 
strain, regulates proinflammatory cytokines, stimulates the production of nitric oxide, reduces oxidative stress, and 
works as a thermogenic source against hypothermia. Conversely, EAT has pathologic paracrine interactions with 
the surrounded vessels, and might favour the onset of atrial fibrillation. In addition, initial atherosclerotic lesions 
can promote inflammation and trigger the EAT production of cytokines increasing vascular inflammation, which, 
in turn, may help the development of collateral vessels but also of self- stimulating, dysregulated inflammatory 
process, increasing coronary artery disease severity. Variations in EAT were also linked to metabolic syndrome. 
Echocardiography first estimated EAT measuring its thickness on the free wall of the right ventricle but does not 
allow accurate volumetric EAT estimates. Cardiac CT (CCT) and cardiac MR (CMR) allow for three- dimensional EAT 
estimates, the former showing higher spatial resolution and reproducibility but being limited by radiation exposure 
and long segmentation times, the latter being radiation- free but limited by lower spatial resolution and reproduc-
ibility, higher cost, and difficulties for obese patients. EAT radiodensity at CCT could to be related to underlying 
metabolic processes. The correlation between EAT and response to certain pharmacological therapies has also 
been investigated, showing promising results. In the future, semi- automatic or fully automatic techniques, machine/
deep- learning methods, if validated, will facilitate research for various EAT measures and may find a place in CCT/
CMR reporting.
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EAT mass has been found to account for around 15–20% of the 
total cardiac mass, weighing around 50 g,6 for an average volume 
around 55 cm3. The correlation between an increased amount 
of EAT and visceral fat with obesity is yet under discussion.7,8 
However, recent works have observed a causal link between obesity 
and accumulation and inflammation of EAT, potentially leading to 
coronary artery disease (CAD) or AF.9
As opposed to PAT, EAT originates from the splanchnopleuric 
mesoderm, as do mesenteric and omental fat.10 Physiologically, 
EAT has been shown to release free fatty acids, which are the 
main metabolites of cardiomyocytes, to keep toxic fatty acids 
at a healthy level, and it has a protective role for the coronary 
arteries against mechanical strain.4 In physiological conditions, 
EAT participates in the regulation of inflammation, regulating 
levels of pro- inflammatory cytokines, stimulates the production 
of nitric oxide, and reduces oxidative stress.11
Moreover, EAT is composed of beige adipose tissue, which 
represents a conversion of white into brown adipose tissue 
following hormonal or temperature signals.12,13 A study by Sacks 
et al14 has revealed EAT as a thermogenic source for defending 
the myocardium and coronary vessels against hypothermia, 
using uncoupling protein-1 production as a marker. Indeed, 
uncoupling protein-1 is typically highly expressed in the beige 
adipose tissue, as it allows the production of heat by uncoupling 
electron transport from the synthesis of adenosine triphosphate, 
thus releasing the energy which would have been used for such 
process in the form of thermic energy.13 The beiging of white 
adipose tissue may be regarded as a metabolic activation, and 
thus as protective against metabolic disease.15 Moreover, an 
active thermogenic adipose tissue helps regulate circulating 
branched- chain amino acids, thus protecting individuals against 
obesity and diabetes.16
On the other hand, EAT, along with perivascular adipose tissue 
in general, has also been hypothesized to play a key role in 
the pathological development of cardiovascular disease, as it 
represents a metabolically active tissue with paracrine interac-
tions with the surrounded vessels.17 Subjects with related pathol-
ogies such as hypertrophic cardiomyopathy or CAD have been 
found to have higher volumes of EAT than average.6 Increased 
EAT volume could be associated with a disruption of its physio-
logical activity of regulating fatty acid levels around the heart.18 
In fact, an excessive uptake of fatty acids by EAT might inter-
fere with myocardial metabolism and with the functionality of 
the cardiac cycle, leading to arrhythmic complications as, for 
instance, the insurgence of AF.19
Moreover, EAT, as visceral adipose tissue, can be a source 
of proinflammatory cytokines. Even before cardiovascular 
pathology is overt and symptomatic, atherosclerotic lesions from 
CAD at an initial stage can promote inflammation and trigger the 
production from EAT of cytokines such as interleukin-1β, inter-
leukin-6, interleukin-6 soluble receptor and tumour necrosis 
factor α.20 This process promotes an increase in EAT volume and 
an amplification of vascular inflammation. This, in turn, on one 
side may help neoangiogenesis and the development of collat-
eral vessels, on the other side, may lead to a self- stimulating, 
dysregulated inflammatory process and the increase in severity 
of CAD.21 By means of the same mechanisms, an increase in EAT 
and its dysfunction may promote the onset of CAD.5 Both EAT 
volume and radiodensity were recently found to be associated 
with serum inflammatory markers, subclinical atherosclerosis 
and major cardiac events.22 EAT inflammation might play a role 
also in the development of AF.23 Talman et al5 provide a compre-
hensive description and depiction of the pathophysiological role 
of EAT in their review.
Thus, an alteration in EAT, such as an increase in volume or 
thickness, or change in density, could be regarded as a marker of 
cardiovascular risk (a preclinical stage of cardiovascular disease), 
as also supported by the finding of modifications in EAT tran-
scriptome in presence of severe CAD.24
More generally, research has also linked variations in EAT with 
the presence of metabolic syndrome, a condition characterized 
by disruption of the physiological pathways regulating inflam-
mation, given the similarities between its metabolic asset and 
that of visceral adipose tissue.8
ImagIng technIques
Given the potential role of EAT in defining cardiovascular risk, 
different non- invasive techniques have been utilized in the 
attempts to provide a reliable quantification of its extent. The 
main methods for assessing EAT have so far been echocardiog-
raphy, CCT, and cardiac MR (CMR).
At echocardiography, EAT appears as a hyperechoic area situ-
ated between the ventricular wall, more prominent around the 
free wall of the right ventricle, and the parietal pericardium.25 
Echocardiography has provided the first estimates of EAT by 
allowing to measure its thickness on the free wall of the right 
Figure 1. Segmentation of EAT in light blue, and PAT in dark 
blue on a contrast- enhanced cardiac CT scan in a 64- year- old 
female patient. EAT, epicardial adipose tissue; PAT, paracardial 
adipose tissue.
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ventricle, where it is usually more prominent. EAT echocardio-
graphic thickness measurements are usually performed perpen-
dicularly to the myocardial wall in parasternal view, and long and 
short axis views.26 Normal values are around 5 mm: Nelson et 
al27 found a mean value of 4.7 ± 1.5 in asymptomatic subjects. In 
fact, some works suggest a cut- off value of 5 mm for EAT thick-
ness to identify individuals at higher cardiovascular risk.28,29 
Echocardiography is relatively inexpensive, widely available, and 
it does not bear limiting contraindications or radiation expo-
sure. However, it presents important limitations such as the fact 
that two- dimensional echocardiography does not allow accurate 
volumetric EAT estimate, and its high dependence on the expe-
rience of the operator.30,31 Some authors have reported confusing 
pericardial effusion with EAT is sometimes possible.31
Alternatively, CCT is a volumetric technique, which allows for 
three- dimensional EAT estimates. EAT may be visible on CCT 
scans as a hypodense layer, with a density usually ranging −190 to 
−30 Hounsfield units,3 comprised between the myocardium and 
the visceral pericardium (Figure 2). EAT may be measured during 
CCT post- processing, not needing specific acquisitions. It can be 
quantified from different scans, most often either unenhanced scans 
for calcium scoring, or CCT angiographic scans, given that the EAT 
and pericardium are similarly visible in both, especially during the 
short time interval intercurrent between contrast administration 
and angiographic acquisition.32,33 Therefore, adding EAT volume 
estimate to the output of a CCT report could provide an additional 
risk estimate for cardiovascular disease, without adding to patient 
discomfort and radiation exposure.
Studies have reported a high reproducibility of EAT quantifica-
tion on CCT scans.34 However, standard electrocardiographically 
gated CCT, if used only for obtaining EAT estimates, could be 
questioned due to the ionizing radiation exposure, even though 
recently, Nagayama et al35 proposed the use of non- gated CCT 
to quantify EAT volumes, achieving excellent concordance with 
gated CCT with reduced radiation dose. Another limitation of EAT 
quantification by CCT angiography stems from long segmentation 
times, as a precise measurement is best performed on numerous 
small slice- thickness images, strongly limiting an integration into 
routine clinical practice. However, CCT allows the quantification 
of EAT X- ray radiodensity, which may be a biomarker of metabolic 
activity of EAT, possibly related to cardiovascular or metabolic 
disease.36 EAT volume has also been assessed on positron emis-
sion tomography/CCT (PET/CCT), to associate anatomical data to 
functional information.37 While to the best of our knowledge no 
meta- analysis has yet defined normal and pathological values for 
CCT- derived EAT volume and density, one study by Spearman et al 
reported values of CCT- derived EAT above 125 ml to be indicators 
of cardiac pathology.38
CMR is, as of now, regarded as the easiest non- invasive approach 
for estimating the EAT volume mass.39 Not unlike CCT, CMR 
is a volumetric technique that can provide highly reproducible, 
three- dimensional EAT measurements.40 EAT can be visualized 
on images obtained with different CMR sequences, however it has 
been often quantified on cine sequences which are performed in 
almost all patients undergoing CMR41 (Figure 3). On cine bright- 
blood steady- state free- precession sequences, EAT may be visu-
alized as a hyperintense, light grey area comprised between the 
hypointense myocardium and visceral pericardium (Figure  4). 
CMR is radiation- free and EAT estimation through CMR does not 
require the use of gadolinium- based contrast agents, whose safety 
has become increasingly debated during the last years.42
Therefore, CMR can be considered a safe technique, provided that 
MRI contraindications are absent, such as marked obesity, claus-
trophobia or MR- unsafe devices.43 In addition, we should consider 
drawbacks of CMR such as high cost, relatively long examination 
times, and limited availability. Obesity is important when EAT 
quantification for the estimation of cardiovascular risk is under 
consideration, as obese people are a growing population which 
could represent an interesting target in this context. Moreover, 
CMR scans generally have greater slice thicknesses than CCT scans, 
limiting the accuracy of EAT volume segmentation performed. In 
fact, to visualize the pericardium on the inferior slices of CMR 
scans is often challenging, as opposed to CCT scans.
A comparison between the main imaging techniques for the 
evaluation of EAT is outlined in Table 1.
Epicardial adipose tissue as an imaging biomarker: 
actual evidence and open questions
Several studies have investigated the potential role of EAT as an 
imaging biomarker of various cardiovascular pathologies. EAT 
has been observed to be an independent risk factor for cardio-
vascular events in both healthy subjects and in patients with 
pre- existing diseases. It has been shown to directly correlate to 
the severity of cardiovascular pathologies, such as CAD, and to 
respond to metabolic changes originating from some pharmaco-
logical therapies.
Longitudinal studies, with sample size ranging up to over 4000 
subjects, have shown that EAT volume calculated from CCT or 
Figure 2. Contrast- enhanced cardiac CT scan of a 64- year- old 
female patient depicting the thin pericardium (white arrow-
heads). The epicardial adipose tissue is immediately internal 
to the pericardium.
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CMR may help predict the onset of arrhythmic complications 
such as AF. In 2010, a study by Thanassoulis et al,44 part of the 
Framingham heart study, identified a strong positive indepen-
dent association between EAT and prevalent AF, promoting a 
growing interest in EAT as imaging biomarker. In 2014, a study 
by Mahabadi et al,45 part of the Heinz Nixdorf Recall study 
assessing novel cardiovascular risk factors in healthy subjects, 
also found a strong correlation between increased EAT and 
the incidence of AF. However, these authors also propose the 
hypothesis of the real predictor being the atrial size, as atrial 
size also bore the same correlation with AF incidence, and 
indexing EAT for atrial size led to a loss of its risk prediction 
potential. In this regard, in 2016, a meta- analysis by Zhu et 
al46 has divided patients for having paroxysmal or persistent 
AF, revealing that the role of EAT might differ with regards to 
the type of AF and underlying remodelling. This observation 
was also confirmed by other studies, investigating the charac-
teristics of EAT in these two different patient groups.47 Thus, 
further studies are needed to clarify the role of EAT as an inde-
pendent predictor of the insurgence of different types of AF.
Concerning CAD, one study by Bastarrika et al48 has observed 
that EAT, especially when quantified from CCT as opposed 
to two- dimensional measurements obtained from echocar-
diography, bears a positive correlation to the extent of CAD, 
assessed by both calcium scoring and stenosis severity. A 
study by Alexopoulos et al49 from 2010 found increased EAT 
in patients with obstructive CAD or non- calcified plaques, 
correlating EAT to high- risk CAD. In 2014, a study by 
Mahabadi et al,50 also part of the Heinz Nixdorf Recall study, 
found that the volume of EAT was associated to the progres-
sion of calcium scores, especially in younger subjects with low 
calcium scores, thus presenting it as a potential early predictor 
of CAD. In 2017, Fuller et al51 identified EAT as a potential risk 
predictor for sudden death related to CAD, from the finding 
that subjects with CAD who died from cardiac- related sudden 
death had significantly higher EAT volumes than those who 
died from other causes. One systematic review by Nerlekar 
et al52 reported that an increased EAT volume can be associ-
ated to the presence of high- risk plaques, though the primum 
movens of this process has yet to be clarified. Another review 
by Spearman et al38 suggested that EAT provided incremental 
value for risk assessment over calcium scoring alone. Overall, 
the role of EAT as a predictor of CAD- related risk, being also 
fully supported by studies conducted on the Framingham 
cohort,53 is more recognized than that related to AF.
Figure 3. Unenhanced (A) and arterial phase contrast- enhanced (B) cardiac computed tomography scans of a 52- year- old male 
patient showing the pericardium(white arrowheads), visible in both images as a thin, hyperdense line. This caseis an example of 
the difficulties in segmenting the epicardial adipose tissue.
Figure 4. Cardiac magnetic resonance true fast imaging with 
steady- state free precession sequence in a 64- year- old female 
patient, showing the pericardium (white arrowhead) as a thin, 
just visible, hypointense line surrounded by hyperintense adi-
pose tissue on both sides.
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Another important topic is the possible use of the radiodensity of 
EAT at CCT as a potential biomarker. Indeed, EAT radiodensity 
might differ according to underlying inflammation or due to the 
different levels of metabolic activity of adipose tissue at different 
browning degrees.36 In 2017, one study by Antonopoulos et al54 
quantified fat radiodensity in epicardial, thoracic, and subcuta-
neous adipose tissue, observing that radiodensity could help in 
the investigation of the characteristics of different adipose tissues. 
Browning of EAT is an alternative explanation and is supported 
by a recent study showing decreased brown fat related genes in 
patients with acute coronary syndrome compared with stable CAD 
or non- CAD.55 Marwan et al56 found a lower radiodensity of peri-
coronary adipose tissue in normal segments compared to patho-
logic ones, however, their finding might also have been affected 
by the presence of contrast media, which may have a higher 
distribution in the pericoronary fat that surrounds atherosclerotic 
segments. Another possible explanation for the variations in EAT 
radiodensity in presence of cardiac pathology could be found in the 
higher metabolic activity of segments with CAD, due to underlying 
inflammation.57 Conversely, Franssens et al58 found a lower EAT 
radiodensity in patients at higher risk of cardiovascular disease, and 
Hell et al59 observed decreased EAT density in patients with higher 
EAT volumes, body mass index, and a family history positive for 
CAD. Another study by Balcer et al60 did not find EAT radioden-
sity differences between segments with or without atherosclerotic 
lesions in patients with acute myocardial infarction. In a recent 
study, Goeller et al22 found a strong association between EAT radi-
odensity and major adverse cardiac events. An increase in EAT 
radiodensity has also been linked to the presence of myocardial 
infarction with nonobstructive coronary arteries, and Tako- Tsubo 
syndrome.61
The correlation between EAT and response to certain pharmaco-
logical therapies has also been investigated. One study by Kang 
et al62 found an increased EAT thickness in CAD patients as a 
predictor of the insurgence of statin- associated diabetes mellitus. 
Moreover, statins have been observed to reduce EAT radiodensity, 
and this reduction can be associated to a decrease in EAT meta-
bolic activity.36 This process, which may be found also in other 
brown adipose tissue deposits, might potentially help explain the 
pathway between statin therapy and the development of diabetes, 
as statins inhibit the browning of fat, and have been linked to EAT 
regression.63–65 These findings are well in agreement with the fact 
that treatment with statins lowers risk of CAD, albeit bearing the 
risk of insurgence of diabetes.66 One work by Ko et al,67 conducted 
in patients undergoing haemodialysis treated with different drugs, 
found a lack of EAT increase during the treatment with sevelamer, 
possibly due to its anti- inflammatory effect.
The association of metabolic information to anatomical data 
stemming from PET/CCT has led to yet debateable findings. A 
higher metabolic activity has been observed by Mazurek et al68 in 
EAT as opposed to other fat deposits, in particular white adipose 
tissue. While one possible interpretation for this finding is that 
the increased uptake was secondary to inflammation in adipose 
tissue,69 the absence of significant differences in EAT between 
patients with or without CAD contradicts this explanation. The 
higher uptake of EAT compared to other deposits could be due to 
the higher metabolic activity of brown adipose tissue compared to 
white.36
future perspectIves
Methods allowing an automatic and reliable EAT segmentation 
gained recently a growing attention, as they would permit to inte-
gration of EAT estimation in routine practice. In this regard, the 
target technique for EAT segmentation would be unenhanced, 
ECG- gated CCT, which is already performed in subjects for the 
evaluation of calcium scoring, so to theoretically obtain two inde-
pendent risk biomarkers from only one scan.70,71 CMR would find 
its main use on patients who already undergo examinations for 
clinical indications, that however do not represent the population 
at higher cardiovascular risk related to CAD. Especially on newer 
scanners, radiation exposure from scans for calcium scoring have 
proven to be extremely low, thus overcoming the main limitation 
of CCT.72 However, manual quantification of EAT on thin, CCT 
angiography slices may be highly time- consuming, and would at 
present not be feasible in routine clinical practice.
Different studies have so far proposed innovative approaches 
to accelerate EAT segmentation at CCT, ranging from semi- 
automatic techniques to fully automatic, deep- learning methods. 
In addition to quickening segmentation times, making EAT 
quantification fit for clinical practice, the adoption of fully auto-
mated segmentation methods would also provide a high repro-
ducibility for EAT volumes.
Nichols et al32 quantified EAT volume, although calling it “peri-
cardial adipose tissue”, with a semi- automatic method on coronary 
CCT angiographic scans. Their results show a very strong correla-
tion between EAT values obtained by two different readers, albeit 
with a slight negative bias. A subsequent study by Barbosa et al73 
proposed a semi- automatic method on unenhanced CCT scans, 
Table 1. Comparison among the main imaging techniques for the evaluation of epicardial adipose tissue.
Advantages Disadvantages
Echocardiography Readily available, inexpensive, quick Highly operator- dependent, no volumetric measurements 
possible, difficult in patients who have motion or breathing 
issues
CCT High definition, volumetric measurements 
possible, best visibility of the pericardium
Long segmentation times at low slice thickness when 
analysing contrast- enhanced series, ionizing radiations
CMR Absence of ionizing radiations, volumetric 
measurements possible, allows quantification 
of attenuation
Expensive, not always available, long scan times, pericardium 
hard to visualize especially at lower sections of the heart, 
contraindicated in some patients
CCT, cardiac CT; CMR, cardiac MR.
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that bore a maximum interoperator error of around 10%. Goeller et 
al22 also used a semi- automatic method, a software named QFAT, 
to quantify EAT volume and radiodensity when studying such 
parameters in relation with CAD.
The first fully automatic EAT segmentation method was presented 
in 2014 by Ding et al74 who used CCT examinations with 2.5–3 mm 
of slice thickness, each data set amounting to 50–60 slices. Auto-
matically segmented EAT displayed a very strong correlation (r = 
0.96) with EAT volume manually quantified by an expert operator; 
the segmentation time was under 60 s on a standard computer. 
However, it also presented difficulties in recognizing the pericar-
dium, especially when segmenting the highest or lowest slices, 
where the pericardial sac is not always clearly visible. In 2018, 
Commandeur et al71 proposed a novel segmentation method 
employing deep learning techniques. So far, they achieved a high 
correlation between automatic and manual EAT measurements (R 
= 0.945), with a non- significant bias (0.12 cm3) at Bland–Altman 
analysis. However, their method still needs validation on larger 
cohorts.
conclusIons
EAT has emerged as an imaging biomarker especially useful for 
predicting CAD and its complications. This, along with the recent 
advances in the development of partially or fully automated 
methods for EAT segmentation may open road to the possibility 
of using EAT as a risk predictor in a clinical setting, adding a 
novel, independent risk biomarker to routine practice and facili-
tate research which presently is cumbersome to perform.
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